Loading company…
Renda Kangjian develops Huperzine A APIs and other products for Alzheimer's disease treatment.
Founded in 2022 in Xianyang, Renda Kangjian researches and develops drugs for Alzheimer's disease and related products. Its main product is Huperzine A APIs made using its biosynthesis technology, and the company holds more than 10 invention patents in the field. In June 2024, it raised a strategic investment of CNY 3 million to support technology development and product promotion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in